6 Psychedelic Clinical Trials That Could Have A Major Impact On The Way We Address Mental HealthPsyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, PPsyched Wellness Is Laser Focused On Uncovering The Medical Properties Associated With MuscimolField Trip Health Has Its Sights Set On Jamaica To Spearhead Future R&D InitiativesPure Extracts Submits Multiple SKUs to Health Canada for ApprovalTryp Therapeutics Has Been Laser Focused On Executing On Its Business Plan Post ListingNuminus Wellness Is Making Major Headway On Its MDMA TrialsPsyched Wellness Closes $6,603,000 Bought Deal Private PlacementMind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with PsychedelicsTryp Therapeutics Completes $2 Million Strategic FinancingCybin Inc. Is Focused On Taking A Quantitative Approach To Tackling DepressionTryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing ProgramTryp Therapeutics Appoints Dr. Joel Castellanos as Clinical AdvisorField Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica3 Functional Mushroom Leaders Investors Need To Be WatchingTryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer MillerNuminus Wellness Completes Acquisition of Montreal-based Mindspace WellbeingTryp Therapeutics Announces Strategic Investment of $2,000,000Psychedelic Clinics Are A Major Vertical That Investors Need To Be Watching

Our Passion Drives Us

Mushroomstocks is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry.

With over 300 publicly traded cannabis companies already in existence and more sprouting up every day, it is difficult for investors to focus on quality companies. Mushroomstocks focuses on companies that are executing on business initiatives and generating value for shareholders.

Our research is our passion! Your profit is our reward.

    • Michael Berger

    • Co-Founder, Mushroomstocks

    • Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Mushroomstocks.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.
    • Anthony Varrell

    • Co-Founder, Mushroomstocks

    • Experienced marketing and investor relations professional. Prior to entering the cannabis industry, Anthony worked on the agency side for Dr. Pepper Snapple launching one of the brands major North American Campaigns. Anthony is currently Managing Director of StoneBridge Partners LLC, advising clients on capital markets strategies and investing in some of the pioneering firms of today’s cannabis industry.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link